Loading...

Living Cell Technologies

OTCPK:LVCL.Y
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LVCL.Y
OTCPK
A$17M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The last earnings update was 95 days ago. More info.


Add to Portfolio Compare Print
  • Living Cell Technologies has significant price volatility in the past 3 months.
LVCL.Y Share Price and Events
7 Day Returns
0%
OTCPK:LVCL.Y
1%
US Biotechs
0.2%
US Market
1 Year Returns
-25.9%
OTCPK:LVCL.Y
-4.6%
US Biotechs
2.9%
US Market
LVCL.Y Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Living Cell Technologies (LVCL.Y) 0% -20% -33.3% -25.9% -42.1% -53.5%
US Biotechs 1% -0% -3.2% -4.6% 3.8% 9.7%
US Market 0.2% -1.6% 2.4% 2.9% 36.1% 41%
1 Year Return vs Industry and Market
  • LVCL.Y underperformed the Biotechs industry which returned -4.6% over the past year.
  • LVCL.Y underperformed the Market in United States of America which returned 2.9% over the past year.
Price Volatility
LVCL.Y
Industry
5yr Volatility vs Market

Value

 Is Living Cell Technologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Living Cell Technologies. This is due to cash flow or dividend data being unavailable. The share price is $0.2.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Living Cell Technologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Living Cell Technologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:LVCL.Y PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$0.00
ASX:LCT Share Price ** ASX (2019-05-22) in AUD A$0.03
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,085 Publicly-Listed Companies 17.79x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Living Cell Technologies.

OTCPK:LVCL.Y PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:LCT Share Price ÷ EPS (both in AUD)

= 0.03 ÷ 0.00

-142.86x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Living Cell Technologies is loss making, we can't compare its value to the US Biotechs industry average.
  • Living Cell Technologies is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Living Cell Technologies's expected growth come at a high price?
Raw Data
OTCPK:LVCL.Y PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -142.86x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.26x
United States of America Market PEG Ratio Median Figure of 2,123 Publicly-Listed Companies 1.54x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Living Cell Technologies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Living Cell Technologies's assets?
Raw Data
OTCPK:LVCL.Y PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.01
ASX:LCT Share Price * ASX (2019-05-22) in AUD A$0.03
United States of America Biotechs Industry PB Ratio Median Figure of 414 Publicly-Listed Biotechs Companies 3.35x
United States of America Market PB Ratio Median Figure of 5,201 Publicly-Listed Companies 1.84x
OTCPK:LVCL.Y PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:LCT Share Price ÷ Book Value per Share (both in AUD)

= 0.03 ÷ 0.01

2.87x

* Primary Listing of Living Cell Technologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Living Cell Technologies is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Living Cell Technologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Living Cell Technologies has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Living Cell Technologies expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Living Cell Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.6%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Living Cell Technologies expected to grow at an attractive rate?
  • Unable to compare Living Cell Technologies's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Living Cell Technologies's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Living Cell Technologies's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:LVCL.Y Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:LVCL.Y Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:LVCL.Y Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -3 0
2018-09-30 1 -3 0
2018-06-30 1 -4 0
2018-03-31 1 -3 -2
2017-12-31 1 -3 -4
2017-09-30 1 -3 -4
2017-06-30 1 -3 -4
2017-03-31 1 -4 -4
2016-12-31 1 -4 -4
2016-09-30 1 -4 -3
2016-06-30 1 -3 -3
2016-03-31 1 -3 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Living Cell Technologies is high growth as no earnings estimate data is available.
  • Unable to determine if Living Cell Technologies is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:LVCL.Y Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Living Cell Technologies Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:LVCL.Y Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 0.00
2018-09-30 0.00
2018-06-30 0.00
2018-03-31 0.00
2017-12-31 -0.01
2017-09-30 -0.01
2017-06-30 -0.01
2017-03-31 -0.01
2016-12-31 -0.01
2016-09-30 -0.01
2016-06-30 -0.01
2016-03-31 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Living Cell Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Living Cell Technologies's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Living Cell Technologies's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Living Cell Technologies's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Living Cell Technologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Living Cell Technologies has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Living Cell Technologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Living Cell Technologies's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Living Cell Technologies does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Living Cell Technologies's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Living Cell Technologies's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Living Cell Technologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Living Cell Technologies Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:LVCL.Y Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.79 -0.11 0.07 3.10
2018-09-30 0.84 -0.24 0.07 3.30
2018-06-30 0.88 -0.37 0.07 3.50
2018-03-31 0.96 -2.06 -0.36 3.71
2017-12-31 1.05 -3.75 -0.31 3.92
2017-09-30 1.11 -3.92 -0.10 4.18
2017-06-30 1.17 -4.09 0.11 4.44
2017-03-31 1.12 -3.95 -0.18 4.46
2016-12-31 1.07 -3.81 -0.46 4.47
2016-09-30 0.96 -3.45 -0.18 3.82
2016-06-30 0.84 -3.09 0.11 3.16
2016-03-31 0.64 -4.59 0.87 2.60
2015-12-31 0.43 -6.10 1.63 2.04
2015-09-30 0.64 -6.57 1.59 1.91
2015-06-30 0.84 -7.04 1.54 1.77
2015-03-31 2.35 -6.50 1.71 1.25
2014-12-31 3.86 -5.96 1.87 0.73
2014-09-30 5.79 -6.37 1.79 0.61
2014-06-30 7.72 -6.78 1.71 0.49
2014-03-31 8.37 -6.34 1.50 0.52
2013-12-31 9.02 -5.91 1.29 0.55
2013-09-30 8.39 -4.44 1.27 0.48
2013-06-30 7.75 -2.98 1.26 0.40
2013-03-31 7.37 -2.85 1.22 0.75
2012-12-31 6.99 -2.72 1.19 1.10
2012-09-30 5.79 1.48 1.50 1.86
2012-06-30 4.60 5.68 1.81 2.62

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Living Cell Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Living Cell Technologies has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Living Cell Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Living Cell Technologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Living Cell Technologies has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Living Cell Technologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Living Cell Technologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Living Cell Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Living Cell Technologies has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Living Cell Technologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Living Cell Technologies has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Living Cell Technologies Company Filings, last reported 4 months ago.

OTCPK:LVCL.Y Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 5.78 0.00 5.42
2018-09-30 5.78 0.00 5.42
2018-06-30 7.14 0.00 6.86
2018-03-31 7.14 0.00 6.86
2017-12-31 5.76 0.00 5.25
2017-09-30 5.76 0.00 5.25
2017-06-30 7.52 0.00 7.53
2017-03-31 7.52 0.00 7.53
2016-12-31 9.42 0.00 8.62
2016-09-30 9.42 0.00 8.62
2016-06-30 5.68 0.00 5.30
2016-03-31 5.68 0.00 5.30
2015-12-31 3.68 0.00 3.60
2015-09-30 3.68 0.00 3.60
2015-06-30 5.13 0.00 5.14
2015-03-31 5.13 0.00 5.14
2014-12-31 10.53 0.00 6.97
2014-09-30 10.53 0.00 6.97
2014-06-30 8.43 0.00 4.55
2014-03-31 8.43 0.00 4.55
2013-12-31 11.76 0.00 5.39
2013-09-30 11.76 0.00 5.39
2013-06-30 13.25 0.00 4.50
2013-03-31 13.25 0.00 4.50
2012-12-31 14.53 0.00 2.35
2012-09-30 14.53 0.00 2.35
2012-06-30 14.35 0.00 3.17
  • Living Cell Technologies has no debt.
  • Living Cell Technologies has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Living Cell Technologies has sufficient cash runway for 1.8 years based on current free cash flow.
  • Living Cell Technologies has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of -6.3% each year.
X
Financial health checks
We assess Living Cell Technologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Living Cell Technologies has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Living Cell Technologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Living Cell Technologies dividends.
If you bought $2,000 of Living Cell Technologies shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Living Cell Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Living Cell Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:LVCL.Y Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2005 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Living Cell Technologies has not reported any payouts.
  • Unable to verify if Living Cell Technologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Living Cell Technologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Living Cell Technologies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Living Cell Technologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Living Cell Technologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Living Cell Technologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Living Cell Technologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ken Taylor
COMPENSATION A$393,054
TENURE AS CEO 4.8 years
CEO Bio

Dr. Kenneth Taylor, also known as Ken, Ph.D. has been Chief Executive Officer of Living Cell Technologies Limited since July 1, 2014 and has been its Executive Director since August 31, 2018. Dr. Taylor served as Chief Executive Officer of Antipodean Pharmaceuticals Inc. (formerly Antipodean Biotechnology Ltd.). Dr. Taylor served as Acting Chief Executive Officer and NTCELL Program Director of Living Cell Technologies Limited since February 6, 2014. He served as Medical Director and Managing Director for Roche in New Zealand. He served as Managing Director of the Roche UK affiliate since 1990 and also served at Syntex in Palo Alto, California to convert the corporate pharmaceutical company to Roche Bioscience, a research center. He managed the Roche affiliate and also to help Roche find research alliances in the Asia Pacific area. He served a joint appointment in neurosciences at Princeton University and the Squibb Institute of Medical research in Princeton, New Jersey. In 1975, he joined Roche to establish a pharmacology research and clinical pharmacology program in Sydney, Australia. He served as a Director of Antipodean Pharmaceuticals, Inc. Dr. Taylor served as Director of the Foundation for Research, Science and Technology at the New Zealand government's agency for funding scientific research. Dr. Taylor serves as an Adjunct Professor of Pharmacy at the University of Otago, Dunedin, New Zealand. Dr. Taylor has Doctorate Degrees in Pharmaceutical Chemistry and Pharmacology from the University of Otago School of Medicine. In 1986, he completed a Business Management Program at IMD in Lausanne, Switzerland. He completed a postdoctoral fellowship in Pharmacology and Experimental Therapeutics at the Johns Hopkins University School of Medicine in Baltimore, Maryland.

CEO Compensation
  • Ken's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Ken's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure of the Living Cell Technologies management team in years:

0.7
Average Tenure
  • The average tenure for the Living Cell Technologies management team is less than 2 years, this suggests a new team.
Management Team

Ken Taylor

TITLE
CEO & Executive Director
COMPENSATION
A$393K
TENURE
4.8 yrs

Bob Elliott

TITLE
Co-Founder & Director
COMPENSATION
A$50K
AGE
84

Daya Uka

TITLE
Chief Financial Officer
TENURE
0.2 yrs

Janice Lam

TITLE
Chief Operating Officer
TENURE
0.2 yrs

Mark Licciardo

TITLE
Joint Company Secretary
AGE
54
TENURE
3.3 yrs

Elizabeth McGregor

TITLE
Joint Company Secretary
TENURE
0.7 yrs
Board of Directors Tenure

Average tenure and age of the Living Cell Technologies board of directors in years:

8.2
Average Tenure
70.5
Average Age
  • The tenure for the Living Cell Technologies board of directors is about average.
Board of Directors

Bernie Tuch

TITLE
Interim Chairman
COMPENSATION
A$50K
AGE
67
TENURE
0.8 yrs

Ken Taylor

TITLE
CEO & Executive Director
COMPENSATION
A$393K
TENURE
0.8 yrs

Bob Elliott

TITLE
Co-Founder & Director
COMPENSATION
A$50K
AGE
84
TENURE
15.3 yrs

Robert Willcocks

TITLE
Independent Director
COMPENSATION
A$50K
AGE
70
TENURE
8.2 yrs

John Hunter

TITLE
Independent Director
COMPENSATION
A$50K
AGE
71
TENURE
12.8 yrs

Carolyn Sue

TITLE
Non-Executive Director
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Living Cell Technologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Living Cell Technologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The company’s lead product is NTCELL, an alginate coated capsule, which is in clinical trials for the treatment of Parkinson’s disease. It has a research collaboration agreement with the Centre for Brain Research at the University of Auckland to identify and synthesize a pericyte protective agent for treatment of neurodegenerative disease. Living Cell Technologies Limited was founded in 1987 and is based in Melbourne, Australia.

Details
Name: Living Cell Technologies Limited
LVCL.Y
Exchange: OTCPK
Founded: 1987
A$11,428,821
571,441,081
Website: http://www.lctglobal.com
Address: Living Cell Technologies Limited
330 Collins Street,
Level 7,
Melbourne,
Victoria, 3000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX LCT Ordinary Shares Australian Securities Exchange AU AUD 01. Sep 2004
OTCPK LVCL.F Ordinary Shares Pink Sheets LLC US USD 01. Sep 2004
DB LHI Ordinary Shares Deutsche Boerse AG DE EUR 01. Sep 2004
CHIA LCT Ordinary Shares Chi-X Australia AU AUD 01. Sep 2004
OTCPK LVCL.Y SPON ADR Pink Sheets LLC US USD 20. Jul 2007
Number of employees
Current staff
Staff numbers
0
Living Cell Technologies employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/24 00:04
End of day share price update: 2019/05/22 00:00
Last earnings filing: 2019/02/18
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.